Filing identity and reporting period
Important mismatch: The request identifies Riot Platforms, Inc., but the supplied Form 10-Q is for Venaxis, Inc. It covers the quarter and six months ended June 30, 2015, and was signed August 11, 2015. The summary below describes the supplied filing, not Riot Platforms.
Business context and financial results
Venaxis was developing the APPY 1 acute appendicitis test and evaluating its next-generation APPY 2 product. It also had an animal-health licensing arrangement. APPY 1 product sales were limited to European distributors, primarily for initial stocking and market-study orders.
| Metric | Three months ended June 30, 2015 | Six months ended June 30, 2015 | Six months ended June 30, 2014 |
|---|---|---|---|
| Sales | $24,517 | $35,805 | $51,728 |
| Gross profit | $16,421 | $23,702 | $19,821 |
| Gross margin | 67.0% | 66.2% | 38.3% |
| Operating expenses | $2.04 million | $4.28 million | $5.57 million |
| Operating loss | $1.99 million | $4.21 million | $5.50 million |
| Net loss | $2.03 million | $4.22 million | $5.54 million |
| Loss per share, basic and diluted | $0.07 | $0.14 | $0.21 |
Six-month revenue also included $48,349 of amortized license-fee revenue in 2015, compared with $47,349 in 2014. The filing reports no income-tax benefit for either six-month period.
Cash, liquidity, debt, and cash flow
- At June 30, 2015, cash and cash equivalents were $4.87 million and short-term investments were $15.56 million, totaling approximately $20.43 million in cash and liquid investments. Working capital was $19.64 million.
- Total assets were $24.33 million, total liabilities $4.08 million, and stockholders’ equity $20.25 million. Accumulated deficit was $101.04 million.
- Notes and other obligations totaled $2.08 million, including $155,628 current. The debt was primarily mortgage debt, with fixed rates of 3.95% and 5.86%; scheduled principal payments include a $1.27 million maturity in 2018.
- Six-month operating cash use was $3.83 million, versus $4.96 million in 2014. Investing activities provided $5.39 million, principally from net sales of short-term investments; financing activities used $236,000 for debt repayments. Cash increased by $1.33 million to $4.87 million.
Changes versus the prior comparable period
- Six-month sales fell about 31% to $35,805 from $51,728, while gross margin rose to 66.2% from 38.3%; management cautioned that margins vary with low sales volumes, product mix, and overhead. 2014 cost of sales included approximately $15,500 for expired products.
- Six-month net loss narrowed by approximately $1.32 million. SG&A declined 15% and R&D declined 37%, reflecting reduced U.S. commercialization activity after the FDA’s January 2015 decision and lower clinical, regulatory, and APPY 2 spending. Lower expenses were partly offset by higher litigation costs.
- Cash used in operations improved by approximately $1.14 million. Unlike 2014, the six-month 2015 period had no common-stock issuance proceeds; 2014 included approximately $20.12 million of net stock-issuance proceeds.
Outlook, risks, contingencies, and unusual items
- Management expected near-term operating losses, potentially significant, but believed working capital would fund estimated needs through the remainder of 2015 and into 2016. The company was pursuing additional financing, with no assurance it could obtain financing on acceptable terms or at all.
- The FDA issued a January 2015 not-substantially-equivalent (NSE) determination for APPY 1. Management was evaluating U.S. regulatory and commercialization options and international opportunities. Failure to obtain FDA clearance or generate sufficient product revenue could require other business opportunities and could lead to impairment of related patent costs.
- Management was pursuing cost controls, possible partnerships or licensing, APPY 2 development, and other strategic options. The Ceva animal-health license could generate future milestone payments of up to $1.1 million, plus up to $2 million for additional products, and royalties, if applicable milestones and sales occur. The licensee has specified termination rights.
- Two disclosed lawsuits were pending: a contract dispute with a former consultant and a putative securities class action alleging misleading APPY 1 statements. Venaxis disputed the allegations and intended to defend itself. The filing does not provide a clear estimate of potential loss or a quantified litigation contingency.
- The company recorded $5,000 in patent impairment charges in the first half of 2015. It reported recurring losses and negative operating cash flows and noted that the financial statements did not include adjustments for possible effects if it could not continue as a going concern.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is Venaxis, Inc., not Riot Platforms, Inc.
- Check the status and potential impact of the FDA’s APPY 1 NSE determination, U.S. regulatory plans, and any subsequent commercialization progress.
- Assess cash burn, investment liquidity, financing needs, and whether the stated runway into 2016 proved adequate.
- Track APPY 1 sales concentration and scale, APPY 2 spending, and any material developments in the disclosed litigation.
- Review the mortgage’s 2018 principal maturity and the terms, milestones, and termination provisions of the Ceva license.